问题 › AI 正在改变我们所在的行业 › 健康科技与数字健康
问题不在于 AI 能做什么。而在于你的哪部分风险收入份额，会让支付方或竞争对手以更低成本交付。 对数字健康公司来说，这表现在特定位置。关键数字是风险收入份额和参与率，而这个行业的特殊之处在于，成果风险的签约速度快于公司能否承担它的学习速度——12 个月的测量窗口对上 11 个月的销售周期。通用版本的问题和你实际面临的问题，首步行动不同。
问题不在于 AI 能做什么。而在于你的哪部分风险收入份额，会让支付方或竞争对手以更低成本交付。 对数字健康公司来说，这表现在特定位置。关键数字是风险收入份额和参与率，而这个行业的特殊之处在于，成果风险的签约速度快于公司能否承担它的学习速度——12 个月的测量窗口对上 11 个月的销售周期。通用版本的问题和你实际面临的问题，首步行动不同。
多数 AI 战略讨论从能力出发，却无疾而终，因为能力不是决定结果的变量。变量是你在风险收入份额下收费的归因成果，是否会让支付方或竞争对手自己生产时成本大幅降低。
这可以逐行回答。对每条收入线：自动化工作占成本的比例是多少，你的 PMPM 中有多少由该工作之外的因素保护，以及一个可信竞争对手达到参与率和毛利率平价的速度有多快。
通常不舒服的发现是，暴露的线条正是盈利的线条，因为高毛利工作通常是与归因成果挂钩的信息工作。应对很少是更快采用，而是把收费内容转向自动化让其更有价值而非更无价值的方向。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 压力表现为风险收入份额或 PMPM 的压缩，而不是丢失客户。
✓ 支付方在问，为什么归因成果需要这么长时间才能测量。
✓ 更新的竞争对手以你 PMPM 的一小部分，定价相当的参与率和成果。
通常会让情况更糟的做法。 采用工具却不改变风险收入份额下的收费内容，这同时降低你的成本和 PMPM，而把利润率和客户流失留在原地。
It is for you if you run or finance a digital health company and the pressure is showing up as price, not as lost deals. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Competitive Positioning · sample company profile
The move. Convert 2.9M contracted lives into Medicare Advantage outcomes contracts using existing payer integrations and outcomes proof points.
The leak it closes. Prevents value leakage to in-house payer solutions by demonstrating superior 12-month cohort outcomes data
The assumption it rests on. At least 4 of 34 existing health plans will sign MA outcomes contracts within 24 months — the engine put the probability at 0.75.
| Investment required | $1.8-2.4M total over 24 months |
| Expected return | 250-580% over 36 months on $62M base revenue |
| Revenue, year 1 | $2-4M incremental ARR (2-3 MA contracts) |
| Revenue, year 2 | $6-14M incremental ARR (4-7 MA contracts) |
| Revenue, year 3 | $12-25M incremental ARR (8-12 MA contracts) |
| Exit criteria | Abandon if fewer than 2 MA contracts signed by month 18 OR if engagement rate in MA pilot cohort falls below 30% OR if NCQA certification denied |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to AI Horizon, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
通常先内部使用更对，因为这能在向客户承诺前，先产生关于自身经济的证据。除非竞争对手已重置客户预期，此时内部效率来得太晚。
按价格判断，而不是公告。当你所售产出的市场价格开始下降时， disruption 已经到来，无论技术能演示什么。
较小的企业通常有优势，能更快改变收费内容。关键动作是重新定位，这对你来说比对有大量基盘要保护的 incumbents 更便宜。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית